Mumbai, March 5 -- CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival and prolonged hospital stays. Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes.

The company has highlighted the financial burden transplantation imposes on patients in India, emphasizing the high cost of post-transplant care, particularly CMV prophylaxis. Until now, the imported innovator Letermovir 240 mg was priced at over Rs 5 lakh per m...